Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23199743 | 1.00 | LMNA (0.52) | LMNAHTR7TMEM97ALDH1A1MAPT | |
| SCHEMBL23701361 | 0.82 | HRH3 (0.50) | LMNAALDH1A1MAPTTP53HPGD | |
| SCHEMBL23701360 | 0.82 | HRH3 (0.50) | LMNAALDH1A1MAPTTP53HPGD | |
| SCHEMBL23732554 | 0.82 | LMNA (0.43) | LMNAHTR7TMEM97ALDH1A1MAPT | |
| SCHEMBL22014801 | 0.76 | HTR7 (0.43) | LMNAHTR7TMEM97ALDH1A1MAPT | |
| SCHEMBL23701487 | 0.75 | ACACB (0.44) | HTR7TMEM97ALDH1A1MAPTTP53 | |
| SCHEMBL23701485 | 0.75 | ACACB (0.44) | HTR7TMEM97ALDH1A1MAPTTP53 | |
| SCHEMBL24209136 | 0.74 | ALDH1A1 (0.43) | LMNAHTR7TMEM97ALDH1A1MAPT | |
| SCHEMBL23701407 | 0.72 | MAPT (0.48) | ALDH1A1MAPTTP53MAPK1NPC1 | |
| SCHEMBL23732273 | 0.71 | CHRNB2 (0.66) | LMNAALDH1A1MAPTTP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802541-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-04-14 | — | — | EP | disclosed |
| CN-112243440-A | Hexahydroxypyrrolo [3,4-c ] pyrrole derivatives useful as LOX inhibitors | 癌症研究协会皇家癌症医院 | 2021-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | LMNA 983/4885HTR7 2686/4885TMEM97 2345/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | LMNA 983/4885HTR7 2686/4885TMEM97 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.